> ## Content Index
> Fetch the complete content index at: https://chinapharmadesk.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Kelun hands dual chairmanship to Liu Sichuan as antibiotic profit drops 46% and sac-TMT scales
- URL: https://chinapharmadesk.com/kelun-liu-sichuan-succession-sactmt-pivot/
- Published: 2026-11-19T14:54:08.000Z
- Updated: 2026-11-19T14:54:09.000Z
- Description: Sichuan Kelun Pharmaceutical (SZSE: 002422, Notice 2026-087) and Kelun-Biotech (HKEX: 06990) elected Liu Sichuan chairman on Nov 18, 2026 as Chuanning Biotech 9M profit fell 45.6% and sac-TMT scaled.
- Author: Lin Yi
- Tags: Desk brief, Capital, Oncology & ADC, Pipeline

[Sichuan Kelun Pharmaceutical Co., Ltd.](http://epaper.zqrb.cn/html/2026-11/19/content%5F1288828.htm?div=-1&ref=chinapharmadesk.com) (`SZSE: 002422`, Announcements No. `2026-086` and `2026-087`) and its majority-owned oncology biotechnology subsidiary [Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.](https://www.hkexnews.hk/listedco/listconews/sehk/2026/1118/2026111800641%5Fc.pdf?ref=chinapharmadesk.com) (`HKEX: 06990`) simultaneously announced on November 18–19, 2026 that 75-year-old founder Liu Gexin has stepped down as chairman of both boards, handing the dual chairmanship to his 42-year-old son Liu Sichuan. While Liu Sichuan now serves concurrently as chairman, legal representative, and general manager of parent Kelun Pharmaceutical as well as non-executive chairman and nomination-committee chair of Kelun-Biotech—and Liu Gexin retains his director seats and chairs the parent board’s Strategy Committee—the generational handover coincides with a sharp financial divergence across the group’s three listed entities: antibiotic-intermediate subsidiary [Yili Chuanning Biotechnology Co., Ltd.](https://static.cninfo.com.cn/finalpage/2026-10-23/1225615578.PDF?ref=chinapharmadesk.com) (`SZSE: 301301`, Announcement No. `2026-034`) saw nine-month 2026 net profit plunge 45.63% year-on-year to RMB 332.43 million (approx. $46.0 million), whereas parent [Kelun Pharmaceutical’s Q3 2026 recurring net profit (Koufei)](http://static.cninfo.com.cn/finalpage/2026-10-29/1225636308.PDF?ref=chinapharmadesk.com) (`Announcement No. 2026-083`) jumped 124.06% to RMB 361.80 million (approx. $50.0 million) on the back of Kelun-Biotech’s licensing revenue recognition and commercial ramp-up of its `TROP2` antibody-drug conjugate `sacituzumab tirumotecan` (`sac-TMT` / `MK-2870` / `SKB264`, marketed in China as `Jiatailai`).

## How the November 18 board reshuffle divides operational control and capital-allocation authority

Founded by Liu Gexin in 1996 from a restructured Sichuan infusion plant, the Kelun Group operates a three-pillar listed structure: parent Kelun Pharmaceutical (`002422.SZ`, intravenous infusions and generics), Chuanning Biotech (`301301.SZ`, fermentation-derived antibiotic intermediates and synthetic biology, spun off onto ChiNext in December 2022), and Kelun-Biotech (`06990.HK`, ADCs and novel biologics, listed under Hong Kong’s Chapter 18A in July 2023 and tracked in our [Windward Bio respiratory NewCo report](https://chinapharmadesk.com/windward-bio-ipo-kelun-harbour-qyuns/)).

Cross-checking the November 18–19 governance filings across Shenzhen and Hong Kong clarifies how control is partitioned after the handover:

- **Parent Kelun Pharmaceutical (`SZSE: 002422`, Announcements `2026-086` & `2026-087`)**: By a `9-0-0` vote of the Eighth Board of Directors on November 18, 2026, Liu Sichuan (born 1984; general manager since September 2015 and director since June 2009) was elected chairman and legal representative while continuing as general manager. Liu Sichuan holds `8,346,286` shares (`0.52%`) directly and `22,650,600` shares indirectly via three Tongyi Wutong private securities investment funds (`30,996,886` shares combined, or \~`1.95%`). Founder Liu Gexin remains the company’s largest shareholder with **`379,128,280` shares (`23.83%`, of which `84,630,000` shares or `22.3%` were pledged as of September 30, 2026)** and stays on the board as **Chairman of the Strategy Committee** and a director of key subsidiaries.
- **Subsidiary Kelun-Biotech (`HKEX: 06990`, November 18 filing)**: Liu Sichuan was elected Chairman of the Board and Chairman of the Nomination Committee (stepping down from the Remuneration Committee), while Liu Gexin remains a non-executive director and joins the Remuneration Committee. Under his June 20, 2025 non-executive director service contract, Liu Sichuan receives zero director’s fees and zero additional remuneration from Kelun-Biotech for serving as chairman, while CEO and Executive Director Dr. Ge Junyou continues to lead day-to-day R&D and commercial execution.

## What the Q3 2026 statutory income statements reveal: antibiotic-intermediate contraction versus `sac-TMT` and settlement windfalls

The timing of the succession—matched on November 18 by Kelun-Biotech holding its 2026 national distributor conference in Shanghai rather than Chengdu—reflects a fundamental shift in where the group’s earnings and cash flow originate. Auditing the Q3 2026 reports of Kelun Pharmaceutical (`2026-083`) and Chuanning Biotech (`2026-034`, where Kelun Pharmaceutical holds `72.12%` combined equity) shows three distinct earnings drivers:

| Entity & Statutory Line Item (PRC GAAP)                                    | Q3 2026 (Jul–Sep)                | YoY Change   | 9M 2026 (Jan–Sep)                   | YoY Change / Filing Note                                                                    |
| -------------------------------------------------------------------------- | -------------------------------- | ------------ | ----------------------------------- | ------------------------------------------------------------------------------------------- |
| **Kelun Pharmaceutical (002422.SZ, Consolidated)** — Operating revenue     | RMB 4,274.22M (approx. $591.2M)  | +1.93%       | RMB 13,112.75M (approx. $1.81B)     | \-1.24%                                                                                     |
| **Kelun Pharmaceutical** — Net profit attributable to shareholders         | RMB 339.26M (approx. $46.9M)     | **+69.60%**  | RMB 1,467.03M (approx. $202.9M)     | **+22.18%**                                                                                 |
| **Kelun Pharmaceutical** — **Recurring net profit (Koufei)**               | **RMB 361.80M (approx. $50.0M)** | **+124.06%** | **RMB 1,061.17M (approx. $146.8M)** | **\-7.48%**                                                                                 |
| **Kelun Pharmaceutical** — Non-operating income (Yingyewai Shouru)         | —                                | —            | **RMB 711.09M (approx. $98.4M)**    | **+15,223.71%** vs. RMB 4.64M in 9M 2025 (“receipt of settlement payment”)                  |
| **Kelun Pharmaceutical** — Contract liabilities (Hetong Fuzhai)            | —                                | —            | **RMB 247.45M (approx. $34.2M)**    | **\-44.79%** vs. RMB 448.18M at year-end 2025 (“recognition of licensing revenue”)          |
| **Kelun Pharmaceutical** — Minority interest profit (Shaoshu Gudong Sunyi) | —                                | —            | **RMB 307.61M (approx. $42.5M)**    | **+597.45%** vs. RMB 44.10M in 9M 2025 (“profit increase at non-wholly-owned subsidiaries”) |
| **Chuanning Biotech (301301.SZ)** — Operating revenue                      | RMB 785.08M (approx. $108.6M)    | **\-27.80%** | RMB 2,882.80M (approx. $398.7M)     | **\-16.10%**                                                                                |
| **Chuanning Biotech** — Net profit attributable to shareholders            | RMB 54.92M (approx. $7.6M)       | **\-64.91%** | RMB 332.43M (approx. $46.0M)        | **\-45.63%**                                                                                |
| **Chuanning Biotech** — R&D expenses                                       | —                                | —            | RMB 56.42M (approx. $7.8M)          | **\-32.55%** (“reduction in synthetic-biology product R&D spend”)                           |

Three accounting lines in Kelun Pharmaceutical’s Q3 report (`2026-083`) explain the earnings bridge that Liu Sichuan now inherits:

1. **Chuanning Biotech’s cyclical downturn and synthetic-biology R&D pullback**: Over the first nine months of 2026, Chuanning Biotech’s revenue fell 16.10% to RMB 2.88 billion and Q3 single-quarter net profit dropped 64.91% to RMB 54.92 million, prompting management to trim synthetic-biology R&D spending by 32.55% YoY to RMB 56.42 million while rolling over RMB 200 million in 270-day ultra-short-term commercial paper at a 1.52% coupon in October 2026 (`Announcement No. 2026-033`).
2. **A RMB 711.09 million non-operating settlement windfall boosted headline 9M net profit**: While Kelun Pharmaceutical’s headline 9M 2026 net profit rose 22.18% to RMB 1.47 billion, underlying 9M recurring net profit actually declined 7.48% to RMB 1.06 billion. The gap was bridged by RMB 405.86 million in net non-recurring gains, anchored by **RMB 711.09 million in non-operating income** from a legal settlement payment received during the period (partially offset by RMB 346.11 million attributable to minority shareholders and taxes).
3. **Kelun-Biotech’s `sac-TMT` commercial and MSD milestone engine drove the Q3 operational inflection**: In Q3 2026 alone, Kelun Pharmaceutical’s recurring net profit surged 124.06% YoY to RMB 361.80 million, while contract liabilities on the consolidated balance sheet fell 44.79% (by RMB 200.73 million) as upfront and milestone payments under licensing agreements were recognized as revenue, and minority-interest profit jumped nearly sevenfold (`+597.45%`) to RMB 307.61 million.

## The `sac-TMT` (`MK-2870`) clinical and regulatory scorecard across China and Merck & Co.’s 15+ global Phase 3 trials

With traditional intravenous infusions capped by regional Volume-Based Procurement (`VBP`) and Chuanning’s fermentation margins normalizing, Kelun Group’s valuation rests on `sacituzumab tirumotecan` (`sac-TMT`), which integrates an irreversible pyrimidine-sulfone antibody conjugation linker (`KthLink`) with a novel belotecan-derived topoisomerase I payload (`KL610023`).

In China, `sac-TMT` (`Jiatailai`) is completing its first full commercial year under the [National Reimbursement Drug List (NRDL)](https://chinapharmadesk.com/china-2026-nrdl-commercial-list-bridge/) across late-line triple-negative breast cancer (`TNBC`, `OptiTROP-Breast01`) and `EGFR`\-mutant non-small cell lung cancer (`NSCLC`, `OptiTROP-Lung03` / `OptiTROP-Lung04`), with a sixth China NDA—covering first-line recurrent or metastatic `TNBC` with `PD-L1 CPS < 10`—accepted by the `NMPA` in July 2026, and Phase 3 first-line `PD-L1`\-negative non-squamous `NSCLC` data (`OptiTROP-Lung06`, `sac-TMT` \+ `pembrolizumab` vs. chemotherapy + `pembrolizumab`, `LBA66`) published in *The New England Journal of Medicine* (`doi:10.1056/NEJMoa2611280`) in late 2026.

Outside Greater China, partner Merck & Co. (`NYSE: MRK`, known as `MSD` ex-U.S./Canada) has advanced `MK-2870` (`sac-TMT`) into more than 15 global Phase 3 trials—achieving positive dual primary endpoints (`OS` and `PFS`) in May 2026 in second-line advanced endometrial cancer (`TroFuse-005` / `ENGOT-en23` / `GOG-3095`, `LBA11`) to support `sac-TMT`’s first U.S. Biologics License Application (`BLA`), while actively recruiting large global Phase 3 cohorts across post-neoadjuvant `TNBC` (`MK-2870-012`, `NCT06393374`, *n* \= 1, 530), first-line `TNBC` (`TroFuse-011`, `NCT06841354`, *n* \= 1, 000), platinum-sensitive ovarian maintenance (`TroFuse-022`, `NCT06824467`, *n* \= 770), mismatch-repair-proficient endometrial cancer (`TroFuse-033`, `NCT06952504`, *n* \= 1, 123), and cervical cancer maintenance (`TroFuse-036`, `NCT07216703`, *n* \= 1, 023).

Three milestones will test Liu Sichuan’s dual chairmanship over the next 12 months: whether Kelun-Biotech turns full-year GAAP operating profit positive in FY2026 on domestic `NRDL` hospital volume for `sac-TMT` without relying on one-off settlement income at the parent level; U.S. FDA acceptance and review of Merck’s initial `BLA` for `MK-2870` (`sac-TMT`) following the `TroFuse-005` and `OptiTROP-Lung04`/`Lung06` readouts; and whether parent Kelun Pharmaceutical’s RMB 1.16 billion in current maturing medium-term notes ( up 446.47% as of September 30, 2026) and Chuanning Biotech’s synthetic-biology pipeline stabilize group cash flow in 2027.